JP6858181B2 - 免疫チェックポイントブロッカーを用いる治療の臨床アウトカムを予測するための診断マーカーとしてのｇｄｆ−１５ - Google Patents

免疫チェックポイントブロッカーを用いる治療の臨床アウトカムを予測するための診断マーカーとしてのｇｄｆ−１５ Download PDF

Info

Publication number: JP6858181B2
Authority: JP; Japan
Prior art keywords: hgdf; cancer; antibody; gdf; human
Prior art date: 2015-10-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

JP2018516740A

Other languages

English (en)

Japanese (ja)

Other versions

JP2018535404A (ja

JP2018535404A5 (2

Inventor

イェルク・ヴィッシュフーゼン

マルクス・ハーケ

ラインハルト・ドゥマー

マティアス・メーリング

Original Assignee

ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-10-02

Filing date

2016-09-30

Publication date

2021-04-14

2015-10-02 Priority claimed from GBGB1517527.6A external-priority patent/GB201517527D0/en

2016-04-29 Priority claimed from GBGB1607800.8A external-priority patent/GB201607800D0/en

2016-09-30 Application filed by ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク filed Critical ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク

2018-11-29 Publication of JP2018535404A publication Critical patent/JP2018535404A/ja

2021-01-21 Publication of JP2018535404A5 publication Critical patent/JP2018535404A5/ja

2021-04-14 Application granted granted Critical

2021-04-14 Publication of JP6858181B2 publication Critical patent/JP6858181B2/ja

Status Active legal-status Critical Current

2036-09-30 Anticipated expiration legal-status Critical

Links

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Physics & Mathematics (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Medicinal Chemistry (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Optics & Photonics (AREA)
Peptides Or Proteins (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Oncology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)

JP2018516740A 2015-10-02 2016-09-30 免疫チェックポイントブロッカーを用いる治療の臨床アウトカムを予測するための診断マーカーとしてのｇｄｆ−１５ Active JP6858181B2 (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GBGB1517527.6A GB201517527D0 (en)	2015-10-02	2015-10-02	GDF-15 as a diagnosis marker to predict the clinical outcome of a treatment with immune checkpoint blockers
GB1517527.6		2015-10-02
GB1607800.8		2016-04-29
GBGB1607800.8A GB201607800D0 (en)	2016-04-29	2016-04-29	GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
PCT/EP2016/073519 WO2017055612A1 (en)	2015-10-02	2016-09-30	Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers

Publications (3)

Publication Number	Publication Date
JP2018535404A JP2018535404A (ja)	2018-11-29
JP2018535404A5 JP2018535404A5 (2)	2021-01-21
JP6858181B2 true JP6858181B2 (ja)	2021-04-14

Family

ID=57123979

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2018516740A Active JP6858181B2 (ja)	2015-10-02	2016-09-30	免疫チェックポイントブロッカーを用いる治療の臨床アウトカムを予測するための診断マーカーとしてのｇｄｆ−１５

Country Status (10)

Country	Link
US (2)	US11262360B2 (2)
EP (2)	EP4321866A3 (2)
JP (1)	JP6858181B2 (2)
KR (1)	KR102621034B1 (2)
AU (1)	AU2016333538B2 (2)
CA (1)	CA3000290C (2)
DK (1)	DK3356827T3 (2)
ES (1)	ES2968226T3 (2)
FI (1)	FI3356827T3 (2)
WO (1)	WO2017055612A1 (2)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS59045B1 (sr) *	2012-09-26	2019-08-30	Univ Wuerzburg J Maximilians	Monoklonalna antitela za faktor 15 rasta i diferencijacije (gdf-15)
US10509045B2 (en)	2015-05-29	2019-12-17	University Of Florida Research Foundation, Incorporated	Methods for diagnosing Huntington's disease
FI3356827T3 (fi)	2015-10-02	2024-01-03	Univ Wuerzburg J Maximilians	GDF-15 diagnostisena markkerina immuunivasteen vapauttajilla annetun hoidon hoitovasteen ennustamiseksi
US10940161B2 (en)	2016-04-04	2021-03-09	University Of Florida Research Foundation, Incorporated	Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
KR102433503B1 (ko)	2016-05-24	2022-08-18	노보 노르디스크 에이/에스	Mic-1 화합물 및 이것의 사용
WO2018195110A1 (en)	2017-04-17	2018-10-25	University Of Florida Research Foundation, Incorporated	Regolation of ran translation by pkr and eif2a-p pathways
TWI710377B (zh)	2017-05-23	2020-11-21	丹麥商諾佛儂迪克股份有限公司	Ｍｉｃ－１化合物及其用途
EP3688020A4 (en)	2017-09-25	2021-07-14	University of Florida Research Foundation, Incorporated	IMMUNOASSAYS FOR DETECTION OF RAN PROTEINS
EP3935581A4 (en)	2019-03-04	2022-11-30	Iocurrents, Inc.	DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
KR102164432B1 (ko)	2019-09-18	2020-10-13	한국과학기술원	Dna 메틸화 변이를 이용한 면역항암치료 반응성 예측방법
WO2021055880A1 (en)	2019-09-20	2021-03-25	University Of Florida Researchfoundation, Incorporated	Detection of antibodies against ran proteins from serum and tissue lysates
KR102238912B1 (ko)	2020-05-27	2021-04-12	한국과학기술원	Dna 메틸화 변이 및 종양 변이 부담을 이용한 면역항암치료 반응성 예측방법
CN112162097B (zh) *	2020-07-24	2022-04-01	广州医科大学	Gdf1作为评估pd-1单抗治疗效果的生物标志物
KR20230107309A (ko)	2020-11-10	2023-07-14	카탈임 게엠베하	항-gdf15 항체 및 암 치료용 투여 용법
CN112698042A (zh) *	2020-12-17	2021-04-23	北京赛诺浦生物技术有限公司	检测人生长分化因子-15的荧光免疫层析试纸条及其制备方法和应用
CN113252905A (zh) *	2021-05-12	2021-08-13	北京赛诺浦生物技术有限公司	人生长分化因子-15磁微粒化学发光检测试剂盒及其应用
CN113702647B (zh) *	2021-08-31	2024-03-15	普十生物科技(北京)有限公司	人生长分化因子15即时检测试剂盒、其制备方法及其应用
KR20230046264A (ko)	2021-09-29	2023-04-05	(주)펜타메딕스	Line-1의 dna 메틸화 변이를 이용한 면역항암치료 반응성 예측방법
CN115831306A (zh) *	2023-02-23	2023-03-21	北京康博众联电子科技有限公司	一种数据分析装置、方法及计算机存储介质
CN116462757A (zh) *	2023-03-24	2023-07-21	科兴生物制药股份有限公司	Gdf15的单域抗体及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5595756A (en)	1993-12-22	1997-01-21	Inex Pharmaceuticals Corporation	Liposomal compositions for enhanced retention of bioactive agents
US6455677B1 (en)	1998-04-30	2002-09-24	Boehringer Ingelheim International Gmbh	FAPα-specific antibody with improved producibility
US6465181B2 (en)	1999-03-25	2002-10-15	Abbott Laboratories	Reagents and methods useful for detecting diseases of the prostate
JP2002543841A (ja)	1999-05-17	2002-12-24	バイオファームゲゼルシャフトツアバイオテクノロジシェンエントヴィックルングウントツムフェルトリーブフォンファルマカエムベーハー	ＴＧＦ−βスーパーファミリーの新規のメンバーであるＧＤＦ―１５の神経保護特性
AU2001288770A1 (en)	2000-09-08	2002-03-22	The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
SI2311873T1 (sl)	2004-01-07	2018-12-31	Novartis Vaccines And Diagnostics, Inc.	M-CSF-specifična monoklonska protitelesa in njihova uporaba
EP2441466B1 (en)	2004-04-13	2014-07-23	St Vincent's Hospital Sydney Limited	MIC-1 inhibiting agent
US20070128636A1 (en)	2005-12-05	2007-06-07	Baker Joffre B	Predictors Of Patient Response To Treatment With EGFR Inhibitors
US20100278843A1 (en)	2007-08-16	2010-11-04	St. Vincent's Hospital Sydney Limited	Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
CN101896192A (zh)	2007-10-09	2010-11-24	圣文森特医院悉尼有限公司	一种通过去除或灭活巨噬细胞抑制因子-1而治疗恶病质的方法
WO2009150255A2 (en)	2008-06-13	2009-12-17	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Markers for predicting response and survival in anti-egfr treated patients
NZ591484A (en)	2008-09-29	2012-09-28	Roche Glycart Ag	Antibodies against human il 17 and uses thereof
EP2209003A1 (en) *	2009-01-16	2010-07-21	F. Hoffmann-Roche AG	Means and methods for differentiating between fibrosis and cirrhosis
US7736861B1 (en)	2009-10-19	2010-06-15	Aveo Pharmaceuticals, Inc.	Tivozanib response prediction
US20120309697A1 (en)	2009-10-28	2012-12-06	Samuel Norbert Breit	Methods of diagnosing and prognosing colonic polyps
US9212221B2 (en)	2010-03-03	2015-12-15	Detroit R & D, Inc.	Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
JP2013526852A (ja)	2010-04-06	2013-06-27	カリスライフサイエンシズルクセンブルクホールディングス	疾患に対する循環バイオマーカー
TWI452136B (zh)	2010-11-17	2014-09-11	中外製藥股份有限公司	A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
EP2714738B1 (en) *	2011-05-24	2018-10-10	Zyngenia, Inc.	Multivalent and monovalent multispecific complexes and their uses
WO2013012648A1 (en)	2011-07-15	2013-01-24	Emory University	Gdf15 in diagnostic and therapeutic applications
US8790651B2 (en)	2011-07-21	2014-07-29	Zoetis Llc	Interleukin-31 monoclonal antibody
CN102321173B (zh)	2011-08-12	2013-04-03	中国医学科学院肿瘤研究所	人源化巨噬细胞抑制因子1单克隆抗体及其应用
EP2565262A1 (en)	2011-08-31	2013-03-06	VTU Holding GmbH	Protein expression
EP3683228A3 (en)	2012-01-26	2020-07-29	Amgen Inc.	Growth differentiation factor 15 (gdf-15) polypeptides
RS59045B1 (sr)	2012-09-26	2019-08-30	Univ Wuerzburg J Maximilians	Monoklonalna antitela za faktor 15 rasta i diferencijacije (gdf-15)
ES2791183T3 (es)	2012-12-21	2020-11-03	Aveo Pharmaceuticals Inc	Anticuerpos anti-GDF15
US11021752B2 (en) *	2013-03-15	2021-06-01	Myriad Genetics, Inc.	Genes and gene signatures for diagnosis and treatment of melanoma
JP2015078138A (ja)	2013-10-15	2015-04-23	株式会社ニックス	小動物防除性樹脂組成物
AU2015206603B9 (en) *	2014-01-14	2019-07-18	Dana-Farber Cancer Institute, Inc.	Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
EP2899544B1 (en) *	2014-01-28	2018-12-26	Roche Diagnostics GmbH	Biomarkers for risk assessment and treatment monitoring in heart failure patients who receive B-type natriuretic peptide guided therapy
KR102410090B1 (ko)	2014-02-21	2022-06-16	넥타르 테라퓨틱스 (인디아) 프라이빗 리미티드	항-ｃｔｌａ－４ 항체 또는 항-ｐｄ－１ 항체와 조합한 ｉｌ－２ｒ베타-선택적 효현제
RS59700B1 (sr)	2014-03-26	2020-01-31	Univ Wuerzburg J Maximilians	Monoklonalna antitela za faktor 15 (gdf-15) rasta i diferencijacije, i njihove upotrebe u lečenju kancerske kaheksije i kancera
PL3197493T3 (pl)	2014-09-25	2021-08-23	Aveo Pharmaceuticals Inc.	Sposoby odwracania kacheksji i przedłużania przeżycia obejmujące podanie modulatora gdf15 i środka przeciwnowotworowego
FI3356827T3 (fi)	2015-10-02	2024-01-03	Univ Wuerzburg J Maximilians	GDF-15 diagnostisena markkerina immuunivasteen vapauttajilla annetun hoidon hoitovasteen ennustamiseksi
CN108463246B (zh)	2015-10-02	2025-02-28	尤利乌斯·马克西米利安维尔茨堡大学	使用人生长分化因子15(gdf-15)抑制剂和免疫检查点阻断剂的联合治疗
GB201517528D0 (en)	2015-10-02	2015-11-18	Julius Maximillians Universitãt Würzburg	GDF-15 as a diagnosis marker for melanoma
CN112912395B (zh)	2018-08-20	2024-08-23	辉瑞公司	抗gdf15抗体、组合物和使用方法

2016
- 2016-09-30 FI FIEP16779036.9T patent/FI3356827T3/fi active
- 2016-09-30 DK DK16779036.9T patent/DK3356827T3/da active
- 2016-09-30 JP JP2018516740A patent/JP6858181B2/ja active Active
- 2016-09-30 EP EP23206060.8A patent/EP4321866A3/en not_active Withdrawn
- 2016-09-30 WO PCT/EP2016/073519 patent/WO2017055612A1/en not_active Ceased
- 2016-09-30 CA CA3000290A patent/CA3000290C/en active Active
- 2016-09-30 AU AU2016333538A patent/AU2016333538B2/en active Active
- 2016-09-30 KR KR1020187012419A patent/KR102621034B1/ko active Active
- 2016-09-30 EP EP16779036.9A patent/EP3356827B1/en active Active
- 2016-09-30 ES ES16779036T patent/ES2968226T3/es active Active
- 2016-09-30 US US15/765,174 patent/US11262360B2/en active Active
2022
- 2022-01-20 US US17/580,245 patent/US12473354B2/en active Active

Also Published As

Publication number	Publication date
ES2968226T3 (es)	2024-05-08
EP3356827B1 (en)	2023-12-06
CA3000290A1 (en)	2017-04-06
EP3356827A1 (en)	2018-08-08
WO2017055612A1 (en)	2017-04-06
US20180292412A1 (en)	2018-10-11
KR102621034B1 (ko)	2024-01-03
JP2018535404A (ja)	2018-11-29
EP4321866A2 (en)	2024-02-14
AU2016333538B2 (en)	2022-03-31
AU2016333538A1 (en)	2018-04-26
KR20180054867A (ko)	2018-05-24
US11262360B2 (en)	2022-03-01
DK3356827T3 (da)	2024-01-08
US12473354B2 (en)	2025-11-18
FI3356827T3 (fi)	2024-01-03
US20220242942A1 (en)	2022-08-04
CA3000290C (en)	2023-02-21
EP4321866A3 (en)	2024-03-20

Legal Events

Date	Code	Title	Description
2018-07-12	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180531
2019-01-29	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190129
2019-09-04	A977	Report on retrieval	Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190904
2019-09-17	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190917
2019-12-17	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191217
2020-03-17	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200317
2020-04-20	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200420
2020-07-20	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200720
2020-10-05	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201005
2020-12-01	A524	Written submission of copy of amendment under article 19 pct	Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20201201
2021-02-09	TRDD	Decision of grant or rejection written
2021-02-22	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210222
2021-03-25	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210323
2021-03-25	R150	Certificate of patent or registration of utility model	Ref document number: 6858181 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150
2024-02-20	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2025-04-04	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2026-03-13	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250

Publication	Publication Date	Title
JP6858181B2 (ja)	2021-04-14	免疫チェックポイントブロッカーを用いる治療の臨床アウトカムを予測するための診断マーカーとしてのｇｄｆ−１５
JP7443298B2 (ja)	2024-03-05	ヒト成長分化因子１５（ｇｄｆ－１５）の阻害剤及び免疫チェックポイントブロッカーを使用する併用療法
JP6840136B2 (ja)	2021-03-10	黒色腫の診断マーカーとしてのｇｄｆ−１５
AU2023202602B2 (en)	2026-05-07	Combination therapy using inhibitors of human Growth and Differentiation factor 15 (GDF-15) and immune checkpoint blockers
EA044887B1 (ru)	2023-10-09	Комбинированное лечение с использованием ингибиторов человеческого фактора роста и дифференцировки 15 (gdf-15) и блокаторов контрольных точек иммунного ответа
HK1256067B (en)	2023-05-05	Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
BR112018006218B1 (pt)	2025-12-09	Uso de inibidores de hgdf-15, kit e combinações
BR122025013944A2 (pt)	2025-07-29	Inibidores de hgdf-15, seus usos, composição, kit, combinações e método in vitro para determinar se uma substância de interesse é um inibidor de hgdf-15